March 05, 2015 7:54 PM ET

Biotechnology

Company Overview of Acceleron Pharma, Inc.

Company Overview

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. It develops sotatercept and ACE-536 that are in Phase II clinical trials to treat anemia and associated complications in patients with ß-thalassemia and myelodysplastic syndromes, and red blood cell disorders; and dalantercept, which is in Phase II clinical trials to inhibit blood vessel formation in tumors through the vascular endothelial growth factor pathway inhibitors. The company is also developing a protein therapeutic candidate, ACE-083, for a first-in-human clinical trial targeting diseases involving musc...

128 Sidney Street

Cambridge, MA 02139

United States

Founded in 2003

Phone:

617-649-9200

Fax:

617-649-9988

Key Executives for Acceleron Pharma, Inc.

Founder, Chief Executive Officer, President and Director
Age: 62
Total Annual Compensation: $400.0K
Chief Medical Officer and Senior Vice President
Age: 58
Total Annual Compensation: $380.7K
Senior Vice President and General Counsel
Age: 43
Total Annual Compensation: $319.3K
Compensation as of Fiscal Year 2013.

Acceleron Pharma, Inc. Key Developments

Acceleron Pharma Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Acceleron Pharma Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, collaboration revenue was $3.7 million against $11.5 million last year. Loss from operations was $14.6 million against $3.5 million last year. Net loss applicable to common stockholders was $17.6 million or $0.55 per basic and diluted share against $18.1 million or $0.64 per basic and diluted share last year. For the year, collaboration revenue was $14.6 million against $57.2 million last year. Loss from operations was $55.5 million against income from operations of $7 million last year. Net loss applicable to common stockholders was $51.3 million or $1.63 per basic and diluted share against $39.0 million or $4.15 per basic and diluted share last year.

Acceleron Pharma Inc. Reports Preliminary Data from the DART Study

Acceleron Pharma Inc. reported new preliminary data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell carcinoma (RCC). The preliminary data from part 1 of the DART study were presented in an oral session at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium held in Orlando, Florida on February 28, 2015. Key preliminary data from part 1 of the DART study; Three cohorts each received dalantercept (0.6, 0.9, or 1.2 mg/kg) subcutaneously once every three weeks and axitinib 5 mg orally twice a day for each 21 day cycle. The 0.9 and 1.2 mg/kg dose levels were expanded. Response rates (RECIST v1.1) of the combination of dalantercept and axitinib: Objective response rate of 25.0% (7 partial responses of 28 patients), stable disease rate of 60.7% (17 of 28 patients), disease control rate at 6 months of 57.1% (16 of 28 patients). The preliminary median progression-free survival (PFS) of dalantercept plus axitinib is 8.3 months across all dose levels tested in part 1. The median PFS of the 0.9 mg/kg cohort has not yet been reached. The most common treatment emergent adverse events were fatigue, diarrhea, dysphonia and peripheral edema. There were no grade 4 or 5 related adverse events. Common adverse reactions expected with axitinib such as diarrhea, hypertension, palmar-plantar erythrodysesthesia, and proteinuria did not increase in incidence or severity when combined with dalantercept. Key details for the ongoing part 2 of the DART study (randomized, double-blind): Part 2 of the DART study is open for enrollment of patients who have received one VEGFR TKI and may have also received 1 prior mTOR inhibitor and/or any number of prior immune therapies. Based on the results from Part 1, dalantercept 0.9 mg/kg was selected as the dose level in Part 2 of the DART study.

Acceleron Pharma, Inc., Q4 2014 Earnings Call, Mar 02, 2015

Acceleron Pharma, Inc., Q4 2014 Earnings Call, Mar 02, 2015

Similar Private Companies By Industry

Company Name Region
Silk Road Medical Inc. United States
Biomira USA Inc. United States
Human Genome Sciences Inc. United States
ImmunO4, LLC United States
Diogenics United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
April 2, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Acceleron Pharma, Inc., please visit www.acceleronpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.